Treatment options in patients with systemic sclerosis-associated interstitial lung disease

from The Lancet Respiratory Medicine in conversation with · host The Lancet Respiratory Medicine

Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Episode metadata supplied by the publisher feed · Published Jan 5, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

Treatment options in patients with systemic sclerosis-associated interstitial lung disease

0:00 15:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lancet Respiratory Medicine in conversation with?

This episode is 15 minutes long.

When was this The Lancet Respiratory Medicine in conversation with episode published?

This episode was published on January 5, 2021.

Can I download this The Lancet Respiratory Medicine in conversation with episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!